Corporate Finance
Bergs Securities is proud to have acted as certified adviser and financial advisor to Axvik Group in its IPO on Nasdaq First North Growth Market
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue.
Initiator Pharma is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma ’s lead project is pudafensine, where the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial.
Related News
Company news
Bergs securities granted additional authorisations by the swedish financial supervisory authority
Company news
Bergs Securities recruits Jonathan Hedin to its Corporate Finance team